Is Orforglipron Approved? Yes, Approved as Foundayo

What is Orforglipron?

Orforglipron is Eli Lilly’s once-daily oral non-peptide GLP-1 receptor agonist, now approved for obesity in the United States under the brand name Foundayo. The non-peptide structure is the key differentiator — unlike peptide-based oral GLP-1 drugs such as the Wegovy pill and Rybelsus (oral semaglutide), orforglipron does not require fasting before dosing or restrictions on food and water intake after administration. For a detailed comparison of all oral GLP-1 compounds, see Oral Obesity Drugs in 2026.

Eli Lilly has already secured the U.S. obesity approval and continues global regulatory submissions for both obesity and type 2 diabetes. Lilly still plans to expand orforglipron into type 2 diabetes later in 2026, while additional global filings and launch decisions continue across the broader development program.

Lilly positions orforglipron as an oral GLP-1 that eliminates the formulation constraints that have historically limited peptide-based oral drugs. This practical advantage is distinct from mechanism of action — orforglipron activates the same GLP-1 receptor as semaglutide, but delivers it in a structurally different oral format.

What Did the ATTAIN-1 Phase 3 Trial Show?

In August 2025, Eli Lilly reported positive Phase 3 obesity data from the ATTAIN-1 trial. The headline figures: the highest dose (36 mg once daily) lowered body weight by an average of 12.4% at 72 weeks — equivalent to 27.3 pounds — versus 0.9% for placebo. Orforglipron is an investigational, once-daily small molecule oral glucagon-like peptide-1 receptor agonist designed to mimic the GLP-1 hormone and activate its receptors throughout the body.

The ATTAIN-1 trial also showed improvements in cardiometabolic risk factors alongside weight reduction. Notably, orforglipron can be taken any time of the day without restrictions on food and water intake, unlike oral semaglutide which requires fasting. Lilly stated that the results support advancement toward regulatory submissions, but no specific submission date has been publicly disclosed.

ACHIEVE-3: Orforglipron vs Oral Semaglutide

A pivotal head-to-head clinical trial, ACHIEVE-3, compared orforglipron and oral semaglutide in 1,698 participants with type 2 diabetes over 52 weeks, using four treatment arms: orforglipron 12 mg, orforglipron 36 mg, oral semaglutide 7 mg, and oral semaglutide 14 mg. Orforglipron delivered superior blood sugar control compared to oral semaglutide, lowering A1C by 2.2% versus 1.4%. Participants on orforglipron 36 mg lost 19.7 lbs (9.2%) compared to 11.0 lbs (5.3%) with oral semaglutide 14 mg, representing a 73.6% greater relative weight loss.

Orforglipron showed clinically meaningful improvements from baseline across key cardiovascular risk factors, including non-HDL cholesterol, HDL cholesterol, VLDL cholesterol, total cholesterol, systolic blood pressure, and triglycerides. Discontinuation rates due to adverse events were higher for orforglipron (about 9–10%) compared to oral semaglutide (4–5%), mainly due to gastrointestinal symptoms. The most common adverse events included nausea, diarrhea, vomiting, dyspepsia, and decreased appetite. Orforglipron is also being investigated for treating hypertension and obstructive sleep apnea.

The ACHIEVE Phase 3 global clinical development program for orforglipron has enrolled more than 6,000 people with type 2 diabetes. Research suggests tirzepatide may be more effective than orforglipron for both weight loss and blood sugar control. The lead investigator for the ACHIEVE-3 trial is based at Texas Southwestern Medical Center.

What Happens Next?

Three developments define the near-term path for orforglipron:

1. U.S. launch execution. The obesity approval is already secured, so the next practical milestone is how quickly Foundayo scales through LillyDirect, retail pharmacies, and payer coverage in the United States.

2. Additional label expansion data. The ATTAIN and ACHIEVE programs continue to generate obesity and type 2 diabetes data. Those readouts matter less for the base obesity approval answer now, and more for label expansion, payer positioning, and cross-indication strategy.

3. Competitive positioning. The key commercial question is now how Foundayo stacks up against the Wegovy pill and injectable leaders. Its non-peptide format and no-fasting routine are the clearest differentiators. For a direct efficacy comparison, see Retatrutide vs Orforglipron, and for broader pipeline context use the obesity drug approval tracker.

Why Does This Matter Now?

Orforglipron is one of the most closely watched investigational obesity drugs in the pipeline because it represents a structurally different approach to oral GLP-1 therapy. The development of orforglipron is the result of extensive drug research, including preclinical pharmacology studies and Phase 3 clinical trials, highlighting the scientific innovation behind its creation. If approved, it would be the first non-peptide oral GLP-1 agonist for obesity — a meaningful distinction from the peptide-based Wegovy pill.

The practical implications are significant. Advances in genetic medicine and small molecule drug design are transforming the landscape of obesity and diabetes treatment. Peptide-based oral drugs require specific dosing conditions — empty stomach, small amounts of water, waiting periods before eating — that affect real-world adherence. A non-peptide oral GLP-1 without those restrictions could change the convenience calculus for patients and prescribers. For verified research peptide suppliers, see our best research peptides 2026 guide.